New LD-DTO Solutions Likely
During 2020 we saw a measurable uptick in the number of FDA approved therapies that were LD-DTO….. which you should know stands for Limited Distribution,
February 5, 2021
During 2020 we saw a measurable uptick in the number of FDA approved therapies that were LD-DTO….. which you should know stands for Limited Distribution,
The FDA has approved a new, first ever therapy for Lupus nephritis, Lupkynis (voclosporin) from Aurinia Pharmaceuticals, in combination with background immunosuppressive therapy. It is
The 340b program is once again in the news. All the wailing and gnashing of teeth over recent years boiled over on 2020 with a
Last week the FDA approved a new specialty therapy for adult HIV positive patients. Be patient, it will take some time to explain this announcement
An acquisition that has material implications for the specialty pharmacy industry was announced last week. Shields Health Solutions acquired ExceleraRx for an undisclosed amount. Like
The FDA actually did a remarkable job in 2020 approving new drugs. In spite of the pandemic they managed to approve 53 novel drugs. That’s
WOW….. Centene is ponying up $2.2 billion to acquire Magellan Health! This comes on the heels of Centene’s recently announced acquisition of PANTHER Rx only
We recently sent an RxReport detailing the FDA approval of Orgovyx as the last FDA approval in 2021. That was technically correct….. but there is
The FDA approved the last specialty therapy for 2020 just in time for Christmas. The new oral drug, Orgovyx from four-year-old Myovant Sciences, is indicated
December 29, 2020Winter Garden, FL More catching up —The FDA approved another specialty therapy earlier this month. The new approval is Margenza (margetuximab-cmkb) from MacroGenics and
